Editas and BlueRock join forces — and platform technologies — on a new wave of engineered cell therapies
Two prominent Boston-based biotechs are tying their platform technologies together to see how they can give each other a boost to their respective pipelines.
In a deal announcement shorn of any mention of cash, the gene editing pioneers at Editas have agreed to share their CRISPR platform with BlueRock, a well funded stem cell player — which launched with a $225 million round — looking to play a leading role in the second wave of drug development going on now in the regenerative medicine field.
Editas’ primary interest will be pursuing new, engineered cell medicines for solid tumors and blood cancers while BlueRock wants to apply CRISPR tech for neurology, cardiology and immunology.
“BlueRock and Editas share a common belief in the disruptive potential of utilizing an engineered cell as a therapeutic,” noted BlueRock CEO Emile Nuwaysir. And Cindy Collins, the interim chief of Editas in the wake of Katrine Bosley’s recent sudden departure, mentioned the value of creating off-the-shelf allogeneic meds.
They also mention development, regulatory, commercial milestones and royalties on anything they work on, provided it gets past regulators, of course. But we don’t have the particulars.